The clinical relevance of different antiphospholipid antibody profiles in pediatric rheumatology patients
Authors' conclusion
An initial high-risk aPL profile was persistent in approximately 90% of our cohort, a third of whom had thrombosis, and half had non-thrombotic aPL manifestations.
Study context
- Population
- Pediatric (age ≤ 18) rheumatology patients with at least one positive aPL (LA, anticardiolipin (aCL) IgG/M, or aβ2GPI IgG/M) result, electronic medical records 2016–202242 with subsequent aPL results
- Participants
- 57 participants
- Exposure
- High-risk vs low-risk aPL profiles
- High-riskn = 34
- Low-riskn = 23reference
- Outcome
- Persistent aPL positivity on subsequent testing
Methodological detailssingle center, descriptive analysis
- Single center
- Descriptive analysis
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | High-risk | Low-risk |
|---|---|---|
| Moderate-to-large vessel or microvascular thrombosis in patients with persistently positive aPL | 28% | 0 events |
- Moderate-to-large vessel or microvascular thrombosis in patients with persistently positive aPL: of 32 patients with persistently positive aPL
Non-thrombotic aPL-related manifestations in patients with persistent aPL positivity
- Patients with non-thrombotic aPL-related manifestations
- 15 (47%)
Original publication
The clinical relevance of different antiphospholipid antibody profiles in pediatric rheumatology patients. Pediatr Rheumatol Online J. Published 26 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →